https://scholars.lib.ntu.edu.tw/handle/123456789/584457
標題: | Subsequent risk of acute urinary retention and androgen deprivation therapy in patients with prostate cancer: A population-based retrospective cohort study | 作者: | Yang T.-K. Wu C.-C. Chang C.-H. Muo C.-H. CHAO-YUAN HUANG Chung C.-J. |
關鍵字: | Acute urinary retention; Androgen deprivation therapy; Luteinizing hormone-releasing hormone; Orchiectomy; Prostate cancer | 公開日期: | 2020 | 出版社: | Lippincott Williams and Wilkins | 卷: | 99 | 期: | 7 | 起(迄)頁: | e18842 | 來源出版物: | Medicine (United States) | 摘要: | Acute urinary retention (AUR) is associated with hormone imbalance in men. However, limited studies focused on exploring the complications of AUR in patients with prostate cancer (PC) who receive androgen deprivation therapy (ADT). Therefore, we aim to evaluate the subsequent risk of AUR in ADT-treated PC patients. We collected data from 24,464 male patients who were newly diagnosed with prostate malignancy from a longitudinal health insurance database of catastrophic illness in 2000 to 2008. All PC patients were categorized into 2 cohorts, namely, ADT cohort and non-ADT cohort, based on whether or not the patient receives ADT. The patients were followed up until the occurrence of AUR. Multivariate Cox proportional hazard regression and Kaplan-Meier analysis were performed. After a 12-year follow-up, the incidence rates of AUR were 12.49 and 9.86 per 1000 person-years in ADT and non-ADT cohorts, respectively. Compared with the non-ADT cohort, the ADT cohort had a 1.21-fold increase in AUR risk based on the adjusted model (95% CI = 1.03-1.43). In addition, PC patients receiving early ADT treatment within 6 months or receiving only luteinizing hormone-releasing hormone treatment also had significantly increased risk of AUR. ADT was positively associated with AUR risk. PC patients receiving ADT should be informed about the risks of bladder outlet obstruction and AUR, and they may benefit from screening for related risk factors. New guidelines and treatments should be proposed in the future to manage ADT-related lower urinary tract symptoms and reduce the risk of AUR. Copyright ? 2020 the Author(s). Published by Wolters Kluwer Health, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079337732&doi=10.1097%2fMD.0000000000018842&partnerID=40&md5=0b5aff28257eb057adf1b3d78b9b6d9c https://scholars.lib.ntu.edu.tw/handle/123456789/584457 |
ISSN: | 0025-7974 | DOI: | 10.1097/MD.0000000000018842 | SDG/關鍵字: | gonadorelin; goserelin; leuprorelin; triptorelin; antiandrogen; aged; androgen deprivation therapy; Article; bladder obstruction; cancer diagnosis; cancer radiotherapy; cancer risk; cohort analysis; comparative study; controlled study; cystostomy; disease association; follow up; health insurance; human; ICD-9-CM; incidence; Kaplan Meier method; longitudinal study; lower urinary tract symptom; major clinical study; male; multimodality cancer therapy; practice guideline; priority journal; prostate cancer; prostatectomy; retrospective study; terminal disease; urine retention; case control study; middle aged; proportional hazards model; prostate tumor; Taiwan; urine retention; very elderly; Aged; Aged, 80 and over; Androgen Antagonists; Case-Control Studies; Humans; Incidence; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Taiwan; Urinary Retention |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。